Department of Orthopaedics, Institution of Clinical Sciences, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Division of Orthopaedics, Karolinska University Hospital, Stockholm, Sweden.
Cartilage. 2021 Dec;13(1_suppl):1726S-1733S. doi: 10.1177/1947603520967064. Epub 2020 Oct 27.
Full-depth cartilage lesions do not heal spontaneously and may progress to osteoarthritis (OA). Treatment for these lesions is warranted when symptomatic. At younger age, biological treatment remains the gold standard, but treatment in the middle-aged patient remains a clinical challenge and focal metal implants have been proposed. We aim to present the subjective outcome at 2 years and the risk of reoperation for any reason at midterm after surgery with a novel customized implant for focal femoral chondral lesions in the knee.
In a prospective cohort study, 30 patients were included between January 2013 and December 2017 at 9 different clinics in Sweden. The primary outcome was subjective outcome measurements (Visual Analogue Scale [VAS], EuroQoL [EQ5D], Knee injury and Osteoarthritis Outcome Score [KOOS]) at a minimum of 2 years. The secondary outcome was reoperations for any reason during the follow-up period until December 2019 (mean of 55 months) studied retrospectively by analyzing medical records.
The VAS, EQ5D, and all the KOOS subscales showed significant improvements from preoperatively to the 2-year follow-up. The VAS showed the greatest improvement at the early (3 months) postoperative stage ( < 0.001). Five (7%) patients underwent reoperations and one of these was revised to hemiarthroplasty due to OA progression. No implant loosening was detected in any of the cases.
This customized resurfacing metal implant showed good safety and patient satisfaction. The risk of OA progression and implant loosening is low. Subjective function and pain improved significantly.
全层软骨损伤不会自发愈合,可能进展为骨关节炎(OA)。当出现症状时,需要对这些损伤进行治疗。在年轻患者中,生物治疗仍然是金标准,但中年患者的治疗仍然是一个临床挑战,因此提出了局部金属植入物的治疗方法。我们旨在介绍一种新的定制股骨髁骨软骨病变植入物的 2 年主观结果和中期任何原因再手术的风险。
在一项前瞻性队列研究中,2013 年 1 月至 2017 年 12 月期间,在瑞典的 9 个不同诊所共纳入 30 名患者。主要结局是至少 2 年的主观结局测量(视觉模拟评分[VAS]、欧洲五维健康量表[EQ5D]、膝关节损伤和骨关节炎结果评分[KOOS])。次要结局是在随访期间因任何原因进行的再次手术,通过分析病历进行回顾性研究。
VAS、EQ5D 和所有 KOOS 亚量表均显示出从术前到 2 年随访时的显著改善。VAS 在早期(3 个月)术后阶段改善最大(<0.001)。5 名(7%)患者接受了再次手术,其中 1 名因 OA 进展而改为半髋关节置换术。在任何病例中均未发现植入物松动。
这种定制的表面金属植入物显示出良好的安全性和患者满意度。OA 进展和植入物松动的风险较低。主观功能和疼痛显著改善。